Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACLX Arcellx	$65.35 +0.9%	$62.90	$47.86 ▼ $107.37	$3.60B	0.28	610,359 shs	1.69 million shs
COLL Collegium Pharmaceutical	$29.93 +0.1%	$28.86	$23.23 ▼ $42.29	$961.65M	0.63	398,915 shs	315,470 shs
RARE Ultragenyx Pharmaceutical	$36.52 -1.6%	$36.59	$29.59 ▼ $60.37	$3.45B	0.25	835,145 shs	2.68 million shs
ZLAB Zai Lab	$34.74 -4.0%	$33.46	$16.01 ▼ $44.34	$3.86B	0.96	909,379 shs	759,523 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACLX Arcellx	0.00%	+3.73%	+2.80%	-0.38%	+18.41%
COLL Collegium Pharmaceutical	0.00%	+0.34%	+1.84%	+0.27%	-7.05%
RARE Ultragenyx Pharmaceutical	0.00%	-1.67%	+7.82%	+0.86%	-11.14%
ZLAB Zai Lab	0.00%	+0.55%	+14.69%	-3.87%	+100.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACLX Arcellx	2.8505 of 5 stars	3.5	3.0	0.0	3.2	2.5	0.0
COLL Collegium Pharmaceutical	3.9843 of 5 stars	3.4	1.0	3.0	1.5	0.8	2.5
RARE Ultragenyx Pharmaceutical	3.9071 of 5 stars	3.5	1.0	3.8	2.1	2.5	0.6
ZLAB Zai Lab	3.3316 of 5 stars	3.4	5.0	0.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACLX Arcellx	3.07	Buy	$111.23	70.21% Upside
COLL Collegium Pharmaceutical	2.75	Moderate Buy	$43.75	46.17% Upside
RARE Ultragenyx Pharmaceutical	2.93	Moderate Buy	$87.00	138.23% Upside
ZLAB Zai Lab	2.75	Moderate Buy	$47.37	36.35% Upside

Current Analyst Ratings Breakdown

Latest COLL, ZLAB, RARE, and ACLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	RARE Ultragenyx Pharmaceutical	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00
6/17/2025	ACLX Arcellx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$110.00
6/16/2025	ACLX Arcellx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$115.00
5/28/2025	RARE Ultragenyx Pharmaceutical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
5/9/2025	ACLX Arcellx	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$133.00 ➝ $93.00
5/9/2025	COLL Collegium Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$36.00 ➝ $37.00
5/9/2025	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$64.00 ➝ $65.00
4/9/2025	COLL Collegium Pharmaceutical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACLX Arcellx	$107.94M	33.37	N/A	N/A	$8.41 per share	7.77
COLL Collegium Pharmaceutical	$631.45M	1.52	$12.37 per share	2.42	$7.10 per share	4.22
RARE Ultragenyx Pharmaceutical	$560.23M	6.16	N/A	N/A	$2.76 per share	13.23
ZLAB Zai Lab	$398.99M	9.67	N/A	N/A	$7.68 per share	4.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACLX Arcellx	-$107.35M	-$2.99	N/A	N/A	N/A	-211.46%	-35.27%	-22.73%	8/14/2025 (Estimated)
COLL Collegium Pharmaceutical	$69.19M	$1.22	24.53	4.97	N/A	6.61%	99.08%	15.14%	8/6/2025 (Estimated)
RARE Ultragenyx Pharmaceutical	-$569.18M	-$5.88	N/A	N/A	N/A	-93.04%	-186.49%	-36.81%	7/30/2025 (Estimated)
ZLAB Zai Lab	-$257.10M	-$2.49	N/A	N/A	N/A	-60.26%	-33.35%	-23.28%	8/5/2025 (Estimated)

Latest COLL, ZLAB, RARE, and ACLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ACLX Arcellx	-$0.84	-$1.13	-$0.29	-$1.13	$19.51 million	$8.13 million
5/8/2025	Q1 2025	COLL Collegium Pharmaceutical	$1.50	$1.49	-$0.01	$0.07	$174.96 million	$177.76 million
5/8/2025	Q1 2025	ZLAB Zai Lab	-$0.50	-$0.45	+$0.05	-$0.45	$118.40 million	$106.49 million
5/6/2025	Q1 2025	RARE Ultragenyx Pharmaceutical	-$1.54	-$1.57	-$0.03	-$1.57	$145.98 million	$139.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACLX Arcellx	N/A	4.93	4.93
COLL Collegium Pharmaceutical	3.30	1.08	1.01
RARE Ultragenyx Pharmaceutical	N/A	2.40	2.24
ZLAB Zai Lab	N/A	3.26	3.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACLX Arcellx	96.03%
COLL Collegium Pharmaceutical	N/A
RARE Ultragenyx Pharmaceutical	97.67%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
ACLX Arcellx	8.35%
COLL Collegium Pharmaceutical	2.51%
RARE Ultragenyx Pharmaceutical	5.50%
ZLAB Zai Lab	4.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACLX Arcellx	80	55.11 million	50.51 million	Optionable
COLL Collegium Pharmaceutical	210	32.13 million	31.33 million	Optionable
RARE Ultragenyx Pharmaceutical	1,294	94.54 million	89.34 million	Optionable
ZLAB Zai Lab	1,869	111.08 million	105.57 million	Optionable

COLL, ZLAB, RARE, and ACLX Headlines

Recent News About These Companies

Oppenheimer Asset Management Inc. Makes New Investment in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

1 hour ago | marketbeat.com

Zai Lab (ZLAB) chief legal officer sells $212k in shares

June 29 at 5:21 PM | investing.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Sells $96,647.75 in Stock

June 28 at 6:31 AM | insidertrades.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Shares Purchased by Mirae Asset Global Investments Co. Ltd.

June 28 at 5:35 AM | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Stock Rating Lowered by Wall Street Zen

June 28 at 2:35 AM | americanbankingnews.com

Zai Lab (NASDAQ:ZLAB) Downgraded to Hold Rating by Wall Street Zen

June 27 at 12:09 AM | marketbeat.com

Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Sells 2,675 Shares of Stock

June 27 at 5:55 PM | marketbeat.com

Ying Du Sells 23,669 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Stock

June 27 at 5:55 PM | marketbeat.com

Zai Lab Limited (ZLAB) - Yahoo Finance

June 27 at 3:35 PM | finance.yahoo.com

Cantor Fitzgerald Expects Reduced Earnings for Zai Lab

June 26, 2025 | americanbankingnews.com

Analysts Offer Predictions for Zai Lab FY2025 Earnings

June 25, 2025 | marketbeat.com

Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Director Sells 13,814 Shares of Stock

June 24, 2025 | insidertrades.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Director William Lis Sells 13,814 Shares

June 23, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?

June 23, 2025 | marketbeat.com

Zai Lab (ZLAB) Delivers Positive ZL-1503 Trial Results in Treatment of Atopic Dermatitis

June 20, 2025 | msn.com

Zai Lab (NASDAQ:ZLAB) Shares Down 5.4% - Time to Sell?

June 20, 2025 | marketbeat.com

Mission Wealth Management LP Buys Shares of 20,000 Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

June 18, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Down - Here's Why

June 17, 2025 | marketbeat.com

Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025

June 13, 2025 | finance.yahoo.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Time to Buy?

June 12, 2025 | marketbeat.com

Cantor Fitzgerald Forecasts Zai Lab FY2026 Earnings

June 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Stocks Getting Rare Double Upgrades From Analysts
By Chris Markoch | June 6, 2025
View 3 Stocks Getting Rare Double Upgrades From Analysts
Why Qualcomm’s Latest Price Target Can't Be Ignored
By Sam Quirke | June 24, 2025
View Why Qualcomm’s Latest Price Target Can't Be Ignored
Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal
By Sam Quirke | June 11, 2025
View Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal
Tesla Bulls and Bears Collide: What Investors Should Know
By Sam Quirke | June 18, 2025
View Tesla Bulls and Bears Collide: What Investors Should Know

COLL, ZLAB, RARE, and ACLX Company Descriptions

Arcellx NASDAQ:ACLX

$65.35 +0.58 (+0.90%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$65.37 +0.02 (+0.03%)

As of 06/27/2025 05:59 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Collegium Pharmaceutical NASDAQ:COLL

$29.93 +0.03 (+0.10%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$29.92 -0.02 (-0.05%)

As of 06/27/2025 04:34 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Ultragenyx Pharmaceutical NASDAQ:RARE

$36.52 -0.60 (-1.62%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$36.15 -0.38 (-1.03%)

As of 06/27/2025 07:27 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Zai Lab NASDAQ:ZLAB

$34.74 -1.45 (-4.01%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$34.73 -0.01 (-0.03%)

As of 06/27/2025 05:12 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time